new model drug catalyst
adjust model reflect human
pharmaceut busi updat new guidanc
project ep ep includ
potenti catalyst
estim rel guidanc human pharma
model revenu guidanc gross margin
tax rate project oper incom
margin estim share count reduct base
current trade calcul ep model
includ project oper margin compar guidanc
least
potenti drug catalyst includ
tradjenta cv outcom trial carolina top-line expect quarter
lilli yet issu top-lin press releas even though trial
complet august consensu expect tradjenta show
superior glimepirid sfu sulfonylurea tradit
associ elev cardiovascular risk said tradjenta
total compani sale result implic
class tradjenta
tanezumab long-term phase trial readout come month yield
safeti clariti novel drug pain associ joint damag
risk see jan report tanezumab safeti issu persist detail
two trial tanezumab partner
trulic cv outcom trial rewind result ada june lilli
report posit top-lin manag character
result paradigm chang
tirzepatid optim titrat schedul data manag gi side effect could
present phase data novel dual-mechan
diabet last octob show strong efficaci high gi side effect
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
enthusiasm new product momentum
balanc premium valuat
project consist revenu growth
margin expans drive durabl ep
transact enhanc long-term growth
base case ep premium peer
median due lilli better growth prospect ep compound-annual-growth-rate
bull case ep
bull case ep
new product drive revenu upsid oper leverag boost ep
forecast price-to-earnings multipl expand strong execut repres
potenti addit upsid beyond bull case
base case ep
base case ep
see solid growth prospect balanc premium valuat new product
launch meet slightli exceed expect pipelin progress continu
bear case ep
bear case ep
us revenu growth miss due competit pressur drive earn
expect clinic trial readout disappoint occur investor
becom concern competit threat key franchis us
quarterli result financi guidanc
verzenio trulic jardianc taltz
result
pipelin news flow includ
outcom studi detail ada jun
extern busi develop
risk achiev price
upsid risk posit financi result
project new product revenu
forecast financi result upsid
product disappoint compel extern
downsid risk financi result fall
short expect face us
compet drug surpris upsid
exhibit new vs old consensu estim new estim reflect human
pharmaceut busi
price
price
price
valuat methodolog risk associ price target rate recommend referenc research report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres
morgan stanley research broadway attent research manag new york ny usa
price data
price data
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
act financi advisor bristol-my squibb compani bristol-
myer connect termin pension oblig
oblig distribut combin lump sum plan particip
elect payment purchas group annuiti contract athen
annuiti life compani wholly-own insur subsidiari athen hold ltd
announc decemb annuiti transact subject customari close
condit bristol-my agre pay fee financi advic
includ transact fee conting upon consumm propos
transact pleas refer note end report
act financi advisor bristol-my squibb compani bristol-
myer relat propos acquisit celgen corpor celgen
announc januari propos transact subject customari close
condit includ bristol-my celgen stockhold approv receipt
customari close condit regulatori approv report inform
provid herein intend provid vote advic ii serv endors
propos transact iii result procur withhold revoc
proxi action secur holder bristol-my agre pay fee
financi servic includ transact fee financ fee
conting upon consumm transact pleas refer note end
report
act financi advisor inc relat
agreement glaxosmithklin plc glaxo creat global consum healthcar
compani contribut consum healthcar busi glaxo
exist consum healthcar busi announc decemb propos
joint ventur subject approv glaxo sharehold customari close
condit includ regulatori approv report inform provid herein
intend provid vote advic ii serv endors propos
transact iii result procur withhold revoc proxi
action secur holder agre pay fee
servic includ transact fee conting upon consumm
propos transact pleas refer note end report
